Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IOVA Iovance Biotherapeutics, Inc.

交易中 12-15 10:28:33 EST

2.14

-0.06

-2.95%

最高2.24	最低2.13	成交量254.27万
今开2.23	昨收2.20	日振幅5.00%
总市值8.48亿	流通市值6.49亿	总股本3.97亿
成交额551.90万	换手率0.84%	流通股本3.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IOVA","market":"US","secType":"STK","nameCN":"Iovance Biotherapeutics, Inc.","latestPrice":2.135,"timestamp":1765812511086,"preClose":2.2,"halted":0,"volume":2542701,"delay":0,"floatShares":304000000,"shares":396967970,"eps":-1.19871,"marketStatus":"交易中","change":-0.065,"latestTime":"12-15 10:28:33 EST","open":2.23,"high":2.24,"low":2.13,"amount":5519013.8869320005,"amplitude":0.05,"askPrice":2.14,"askSize":91684,"bidPrice":2.13,"bidSize":14950,"shortable":3,"etf":0,"ttmEps":-1.19871,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.2,"preHourTrading":{"tag":"盘前","latestPrice":2.24,"preClose":2.2,"latestTime":"09:29 EST","volume":39535,"amount":88130.8882775,"timestamp":1765808999999},"postHourTrading":{"tag":"盘后","latestPrice":2.21,"preClose":2.2,"latestTime":"19:55 EST","volume":101285,"amount":226876.372,"timestamp":1765587321546},"volumeRatio":1.587835,"impliedVol":0.9102,"impliedVolPercentile":0.444},"requestUrl":"/m/hq/s/IOVA/wiki","defaultTab":"wiki","newsList":[{"id":"1151227716","title":"Iovance Biotherapeutics Inc：Iov-Lun-202试验将于2026年推进，针对非鳞状非小细胞肺癌的Lifileucel BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=1151227716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151227716?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:10","pubTimestamp":1762171809,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics Inc：Iov-Lun-202试验将于2026年推进，针对非鳞状非小细胞肺癌的Lifileucel BLA","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"1166982075","title":"Iovance Biotherapeutics公布潜在最佳临床数据，针对晚期非小细胞肺癌的Lifileucel Til细胞治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1166982075","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166982075?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:01","pubTimestamp":1762171277,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公布潜在最佳临床数据，针对晚期非小细胞肺癌的Lifileucel Til细胞治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2565519409","title":"Iovance Biotherapeutics, Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565519409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565519409?lang=zh_cn&edition=full","pubTime":"2025-09-05 21:50","pubTimestamp":1757080200,"startTime":"0","endTime":"0","summary":"北京时间2025年09月05日21时50分，Iovance Biotherapeutics, Inc.股票出现波动，股价大幅拉升5.00%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.88%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905215000a4b677fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905215000a4b677fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2561402577","title":"Iovance Biotherapeutics, Inc.盘中异动 大幅拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561402577","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561402577?lang=zh_cn&edition=full","pubTime":"2025-08-22 22:00","pubTimestamp":1755871243,"startTime":"0","endTime":"0","summary":"北京时间2025年08月22日22时00分，Iovance Biotherapeutics, Inc.股票出现波动，股价快速拉升5.12%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082222004494f4cf61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082222004494f4cf61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"1177990075","title":"异动解读 | Iovance Biotherapeutics盘前大涨27.20%，获加拿大卫生部Amtagvi合规通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1177990075","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177990075?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:38","pubTimestamp":1755592704,"startTime":"0","endTime":"0","summary":"周二盘前，生物技术公司Iovance Biotherapeutics股价大幅上涨27.20%，引起市场广泛关注。消息面上，Iovance Biotherapeutics获得了加拿大卫生部对其产品Amtagvi的合规通知。Amtagvi是Iovance Biotherapeutics的重点产品之一，这次获得加拿大卫生部的合规通知，不仅提升了公司的市场地位，也增强了投资者对公司未来发展前景的信心。分析人士认为，这一利好消息可能会对公司的长期业绩产生积极影响，因此引发了市场的强烈反应。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"1125630895","title":"异动解读 | Iovance Biotherapeutics盘前大涨27.20%，获加拿大卫生部Amtagvi合规通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1125630895","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125630895?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:38","pubTimestamp":1755592702,"startTime":"0","endTime":"0","summary":"生物技术公司Iovance Biotherapeutics今日盘前大涨27.20%，引起投资者广泛关注。该股价的强劲上涨反映了市场对公司最新进展的积极反应。据悉，Iovance Biotherapeutics股价大涨的主要原因是公司获得了加拿大卫生部对其产品Amtagvi的合规通知。Amtagvi是Iovance Biotherapeutics的一款重要产品，这一合规通知的获得不仅提升了投资者对公司产品线的信心，也增强了市场对公司未来发展前景的预期。然而，投资者仍需密切关注公司后续在加拿大市场的具体进展，以及Amtagvi的商业化潜力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"1177106527","title":"盘前异动｜英特尔涨超6%，AEye涨超15%，Iovance飙升20%，Palo Alto Networks绩后涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177106527","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177106527?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:06","pubTimestamp":1755590790,"startTime":"0","endTime":"0","summary":"$英特尔$盘前涨超6%，$软银集团$与$英特尔$签署20亿美元投资协议，软银将以每股23美元的价格购买英特尔普通股；$AEye$盘前涨超15%，与$黑芝麻$科技签署战略合作协议；$Iovance Biotherapeutics$盘前涨超20%，获加拿大卫生部对Amtagvi的合规通知；网络安全巨头$Palo Alto Networks$盘前涨超5%，Q4营收25.4亿美元，高于市场预期的25亿美元；$小赢科技$盘前涨超9%，$Q2$营收大增65.6%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"216ce9b8dee407746c2471036318398e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9505.USD","IE00BMPRXN33.USD","BK4605","LU2023250843.SGD","PANW","LU1917777945.USD","BK4550","IE00BMPRXR70.SGD","LU2355687059.USD","INTC","BK4515","LU1720051108.HKD","LU1720051017.SGD","LU1989764664.SGD","BK4598","BK4588","LU0348723411.USD","LU2148611432.USD","IOVA","LU2023250504.SGD","BK4579"],"gpt_icon":0},{"id":"1139212650","title":"美股夜盘 | AEye 涨超16%，Iovance Biotherapeutics涨超14%，Palo Alto Networks绩后涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139212650","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139212650?lang=zh_cn&edition=full","pubTime":"2025-08-19 08:18","pubTimestamp":1755562720,"startTime":"0","endTime":"0","summary":"美东8月18日，美股夜盘，$英特尔(INTC)$涨超5%，与软银签署20亿美元投资协议；AEye 涨超16%，与$黑芝麻(000716)$科技签署战略合作协议；$Iovance Biotherapeutics(IOVA)$涨超14%，获加拿大卫生部对Amtagvi的合规通知；网络安全巨头$Palo Alto Networks(PANW)$绩后涨近5%，Q4营收25.4亿美元，高于市场预期的25亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4526b843d40f390bebf97cd36114a0ab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU1861220033.SGD","INTC","LU0234570918.USD","LU2125909916.SGD","BK4554","LU1861215975.USD","LU2286300806.USD","BK4097","LU2106854487.HKD","IOVA","BK4560","BK4532","LU1623119135.USD","BK4581","LU2125909759.SGD","PANW","BK4598","IE00B19Z8W00.USD","BK4527"],"gpt_icon":0},{"id":"2560132816","title":"英特尔美股夜盘涨超5%与软银签署20亿美元投资协议；AEye涨近17%与黑芝麻科技签署战略合作协议；IOVA涨超14%获","url":"https://stock-news.laohu8.com/highlight/detail?id=2560132816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560132816?lang=zh_cn&edition=full","pubTime":"2025-08-19 08:12","pubTimestamp":1755562339,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e1762a1fd1464e223bc235648bd9e526","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2355687059.USD","BK4560","LU2023250504.SGD","BK0226","BK4554","BK4527","LU0321505868.SGD","IE00BMPRXN33.USD","LU2265009873.SGD","LU1974910355.USD","LU1861215975.USD","BK4141","LU0234570918.USD","LU1548497426.USD","LU2023250843.SGD","PANW","LU0348723411.USD","IOVA","BK4588","LU2125909759.SGD","BK4575","BK4535","LU1861220033.SGD","BK4550","INTC","LU2543165471.USD","BK4529","IE00B19Z8X17.USD","BK4598","LU1720051108.HKD","000716","LU2286300806.USD","BK4512","BK4605","LU2357305700.SGD","LU1169589451.USD","BK4534","LU0321505439.SGD","BK4579","IE00B19Z9505.USD","LU1923622291.USD","LU2106854487.HKD","BK4612","BK4097","LU1169590202.USD","BK4139","LU1917777945.USD","BK4581","BK4515","BK4602"],"gpt_icon":0},{"id":"1146304120","title":"异动解读 | Iovance Biotherapeutics盘前暴跌28%，业绩不及预期并宣布裁员计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1146304120","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146304120?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:05","pubTimestamp":1754640315,"startTime":"0","endTime":"0","summary":"生物制药公司Iovance Biotherapeutics, Inc.今日盘前股价暴跌28.03%，引发市场广泛关注。这一大幅下跌主要源于公司公布的第二季度财报不及预期，以及宣布的裁员计划。尽管面临当前困境，Iovance仍然重申了其全年产品总收入指导范围为2.5亿至3亿美元，而分析师平均预期为3.0018亿美元。值得注意的是，Iovance股价今年以来已下跌64.3%，反映出市场对该公司长期表现的持续担忧。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"2557651167","title":"Iovance Biotherapeutics, Inc.8月7日成交额为7470.51万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557651167","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557651167?lang=zh_cn&edition=full","pubTime":"2025-08-08 11:12","pubTimestamp":1754622761,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，Iovance Biotherapeutics, Inc.成交额为7470.51万美元，成交额较昨日增加144.69%，当日成交量为2835.71万股。Iovance Biotherapeutics, Inc.于2025年8月7日涨2.33%，报2.64美元，该股过去5个交易日涨2.72%，年初至今跌64.32%，过去60日涨36.79%。该公司正在为潜在的美国监管机构批准和首个自体t细胞治疗实体肿瘤的商业化做准备。其目标是成为创新，开发和提供肿瘤浸润淋巴细胞治疗实体肿瘤癌症患者的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808111251a6da0486&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808111251a6da0486&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"1185596854","title":"异动解读 | Iovance Biotherapeutics夜盘暴跌29%，业绩不及预期并宣布裁员计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1185596854","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185596854?lang=zh_cn&edition=full","pubTime":"2025-08-08 08:07","pubTimestamp":1754611675,"startTime":"0","endTime":"0","summary":"生物制药公司Iovance Biotherapeutics, Inc.周四夜盘交易中股价暴跌29.17%，引发市场广泛关注。这一大幅下跌主要源于公司公布的第二季度财报不及预期，以及宣布的裁员计划。尽管面临当前困境，Iovance仍然重申了其全年产品总收入指导范围为2.5亿至3亿美元，而分析师平均预期为3.0018亿美元。值得注意的是，Iovance股价今年以来已下跌64.3%，反映出市场对该公司长期表现的持续担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"1124845727","title":"异动解读 | Iovance生物科技盘后暴跌30.69%，业绩不及预期且扩大裁员","url":"https://stock-news.laohu8.com/highlight/detail?id=1124845727","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124845727?lang=zh_cn&edition=full","pubTime":"2025-08-08 05:00","pubTimestamp":1754600438,"startTime":"0","endTime":"0","summary":"生物制药公司Iovance Biotherapeutics, Inc.在盘后交易中股价大幅下跌30.69%，跌至1.83美元，引发市场关注。这一暴跌主要源于公司公布的第二季度财报不及预期，以及公司宣布的裁员计划。尽管面临当前困境，Iovance仍然重申了其全年产品总收入指导范围为2.5亿至3亿美元，而分析师平均预期为3.0018亿美元。值得注意的是，Iovance股价今年以来已下跌64.3%，反映出市场对该公司长期表现的持续担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"2557870495","title":"Iovance Biotherapeutics, Inc.8月6日成交额为3053.09万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557870495","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557870495?lang=zh_cn&edition=full","pubTime":"2025-08-07 11:09","pubTimestamp":1754536148,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，Iovance Biotherapeutics, Inc.成交额为3053.09万美元，成交额较昨日增加35.01%，当日成交量为1162.79万股。Iovance Biotherapeutics, Inc.于2025年8月6日跌6.18%，报2.58美元，该股过去5个交易日跌3.37%，年初至今跌65.14%，过去60日涨47.43%。该公司正在为潜在的美国监管机构批准和首个自体t细胞治疗实体肿瘤的商业化做准备。其目标是成为创新，开发和提供肿瘤浸润淋巴细胞治疗实体肿瘤癌症患者的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807110914a6d7c540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807110914a6d7c540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"2557342364","title":"Iovance Biotherapeutics, Inc.8月5日成交额为2261.30万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557342364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557342364?lang=zh_cn&edition=full","pubTime":"2025-08-06 11:04","pubTimestamp":1754449477,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，Iovance Biotherapeutics, Inc.成交额为2261.30万美元，成交额较昨日减少35.88%，当日成交量为817.63万股。Iovance Biotherapeutics, Inc.于2025年8月5日跌2.83%，报2.75美元，该股过去5个交易日跌5.82%，年初至今跌62.84%，过去60日跌13.25%。该公司正在为潜在的美国监管机构批准和首个自体t细胞治疗实体肿瘤的商业化做准备。其目标是成为创新，开发和提供肿瘤浸润淋巴细胞治疗实体肿瘤癌症患者的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806110446a6d5a091&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806110446a6d5a091&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2556847567","title":"Iovance Biotherapeutics, Inc.8月1日成交额为4337.54万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556847567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556847567?lang=zh_cn&edition=full","pubTime":"2025-08-02 11:03","pubTimestamp":1754103797,"startTime":"0","endTime":"0","summary":"美东时间2025年8月1日，Iovance Biotherapeutics, Inc.成交额为4337.54万美元，成交额较昨日增加24.07%，当日成交量为1667.26万股。Iovance Biotherapeutics, Inc.于2025年8月1日涨4.28%，报2.68美元，该股过去5个交易日跌14.38%，年初至今跌63.78%，过去60日跌13.55%。该公司正在为潜在的美国监管机构批准和首个自体t细胞治疗实体肿瘤的商业化做准备。其目标是成为创新，开发和提供肿瘤浸润淋巴细胞治疗实体肿瘤癌症患者的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802110324a470b705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802110324a470b705&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2555588099","title":"Iovance Biotherapeutics, Inc.7月29日成交额为4528.57万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555588099","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555588099?lang=zh_cn&edition=full","pubTime":"2025-07-30 11:05","pubTimestamp":1753844747,"startTime":"0","endTime":"0","summary":"美东时间2025年7月29日，Iovance Biotherapeutics, Inc.成交额为4528.57万美元，成交额较昨日减少33.62%，当日成交量为1573.62万股。Iovance Biotherapeutics, Inc.于2025年7月29日跌1.02%，报2.92美元，该股过去5个交易日跌6.71%，年初至今跌60.54%，过去60日跌12.31%。该公司正在为潜在的美国监管机构批准和首个自体t细胞治疗实体肿瘤的商业化做准备。其目标是成为创新，开发和提供肿瘤浸润淋巴细胞治疗实体肿瘤癌症患者的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730110557a6c8d830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730110557a6c8d830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"2554721967","title":"Iovance Biotherapeutics, Inc.盘中异动 快速拉升5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554721967","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554721967?lang=zh_cn&edition=full","pubTime":"2025-07-28 21:30","pubTimestamp":1753709456,"startTime":"0","endTime":"0","summary":"北京时间2025年07月28日21时30分，Iovance Biotherapeutics, Inc.股票出现异动，股价大幅拉升5.91%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072821305694bf6e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072821305694bf6e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2554713353","title":"Iovance Biotherapeutics, Inc.7月25日成交额为7749.50万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554713353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554713353?lang=zh_cn&edition=full","pubTime":"2025-07-26 11:01","pubTimestamp":1753498884,"startTime":"0","endTime":"0","summary":"美东时间2025年7月25日，Iovance Biotherapeutics, Inc.成交额为7749.50万美元，成交额较昨日减少49.93%，当日成交量为2493.51万股。Iovance Biotherapeutics, Inc.于2025年7月25日跌4.86%，报3.13美元，该股过去5个交易日涨40.36%，年初至今跌57.7%，过去60日跌12.08%。该公司正在为潜在的美国监管机构批准和首个自体t细胞治疗实体肿瘤的商业化做准备。其目标是成为创新，开发和提供肿瘤浸润淋巴细胞治疗实体肿瘤癌症患者的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726110127a46430c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726110127a46430c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"2552480937","title":"Iovance Biotherapeutics, Inc.盘中异动 早盘快速上涨5.16%报2.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552480937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552480937?lang=zh_cn&edition=full","pubTime":"2025-07-17 21:51","pubTimestamp":1752760272,"startTime":"0","endTime":"0","summary":"北京时间2025年07月17日21时51分，Iovance Biotherapeutics, Inc.股票出现异动，股价大幅拉升5.16%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717215112a6afff46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717215112a6afff46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iovance.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1339},{"period":"3month","weight":-0.0308},{"period":"6month","weight":-0.0179},{"period":"1year","weight":-0.7236},{"period":"ytd","weight":-0.7027}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞（TIL）治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.038617},{"month":2,"riseRate":0.5,"avgChangeRate":0.122862},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.04457},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.013596},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.091207},{"month":6,"riseRate":0.454545,"avgChangeRate":0.1436},{"month":7,"riseRate":0.727273,"avgChangeRate":0.047009},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.000211},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.078972},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.022017},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07065},{"month":12,"riseRate":0.545455,"avgChangeRate":0.032272}],"exchange":"NASDAQ","name":"Iovance Biotherapeutics, Inc.","nameEN":"Iovance Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Iovance Biotherapeutics, Inc.,IOVA,Iovance Biotherapeutics, Inc.股票,Iovance Biotherapeutics, Inc.股票老虎,Iovance Biotherapeutics, Inc.股票老虎国际,Iovance Biotherapeutics, Inc.行情,Iovance Biotherapeutics, Inc.股票行情,Iovance Biotherapeutics, Inc.股价,Iovance Biotherapeutics, Inc.股市,Iovance Biotherapeutics, Inc.股票价格,Iovance Biotherapeutics, Inc.股票交易,Iovance Biotherapeutics, Inc.股票购买,Iovance Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}